Mercedes Mitjavila
Overview
Explore the profile of Mercedes Mitjavila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oprea-Lager D, Gontier E, Garcia-Canamaque L, Gauthe M, Olivier P, Mitjavila M, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jun;
50(11):3439-3451.
PMID: 37341747
Purpose: Primary objective was to compare the per-patient detection rates (DR) of [F]DCFPyL versus [F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR)....
2.
Mitjavila M, Jimenez-Fonseca P, Bello P, Pubul V, Percovich J, Garcia-Burillo A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Mar;
50(8):2486-2500.
PMID: 36877234
Background: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought...
3.
Garcia Velloso M, Garcia D, Pena C, Ruano Perez R, Fernandez I, Gomez A, et al.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
. 2023 Jan;
42(1):1-2.
PMID: 36639177
No abstract available.
4.
Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, et al.
Eur J Nucl Med Mol Imaging
. 2022 Apr;
49(10):3529-3537.
PMID: 35389069
Purpose: NETTER-R aimed to determine the efficacy, safety and tolerability of Lu-DOTATATE in patients with progressive, advanced pancreatic neuroendocrine tumours (panNETs) using retrospective real-world data from multiple sites. Methods: This...
5.
Garcia Velloso M, Becerra Garcia D, Pena C, Ruano R, Fernandez I, Gomez A, et al.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
. 2021 Oct;
40(6):341-342.
PMID: 34627727
No abstract available.
6.
Iglesias P, Magallon R, Mitjavila M, Berrocal V, Pian H, Diez J
Endocrinol Diabetes Nutr (Engl Ed)
. 2019 Nov;
67(7):469-485.
PMID: 31740190
The concept of aggressive pituitary tumor (APT) has been precisely defined in recent years. These tumors are characterized by morphological (radiological or histopathological) data of invasion, proliferative activity superior to...
7.
Diez J, Galofre J, Oleaga A, Grande E, Mitjavila M, Moreno P
Endocrinol Diabetes Nutr (Engl Ed)
. 2019 May;
66(8):529.
PMID: 31103462
No abstract available.
8.
Gutierrez L, Mendez S, Mitjavila M, Llop E, Salas C, Ruiz-Casado A
J Cancer Res Ther
. 2019 Mar;
15(1):42-47.
PMID: 30880753
Introduction: Selective internal radiation therapy (SIRT) is increasingly used in different scenarios. Although portal hypertension (PHT) has been described as a nonclinically relevant finding after SIRT, its real incidence could...
9.
Diez J, Galofre J, Oleaga A, Grande E, Mitjavila M, Moreno P
Endocrinol Diabetes Nutr (Engl Ed)
. 2019 Jan;
66(2):74-82.
PMID: 30612901
Introduction: The opinion of professionals about multidisciplinary teams (MDT) in thyroid cancer has not been studied in Spain. This study was intended to ascertain the opinion of specialists about the...
10.
Diez J, Galofre J, Oleaga A, Grande E, Mitjavila M, Moreno P
Endocrinol Nutr
. 2015 Oct;
63(3):e1-15.
PMID: 26456892
Thyroid cancer is the leading endocrine system tumor. Great advances have recently been made in understanding of the origin of these tumors and the molecular biology that makes them grow...